207 related articles for article (PubMed ID: 27694470)
1. The conundrum of malaria chemoprophylaxis.
Shanks D
J Travel Med; 2016 Jun; 23(6):. PubMed ID: 27694470
[TBL] [Abstract][Full Text] [Related]
2. Atovaquone-proguanil chemoprophylaxis in the era of Tafenoquine.
Meltzer E; Schwartz E
J Travel Med; 2019 Jun; 26(4):. PubMed ID: 30535377
[No Abstract] [Full Text] [Related]
3. Effectiveness of twice a week prophylaxis with atovaquone-proguanil (Malarone®) in long-term travellers to West Africa.
Lachish T; Bar-Meir M; Eisenberg N; Schwartz E
J Travel Med; 2016 Jun; 23(6):. PubMed ID: 27625401
[TBL] [Abstract][Full Text] [Related]
4. Comparative benefit of malaria chemoprophylaxis modelled in United Kingdom travellers.
Toovey S; Nieforth K; Smith P; Schlagenhauf P; Adamcova M; Tatt I; Tomianovic D; Schnetzler G
Travel Med Infect Dis; 2014; 12(6 Pt B):726-32. PubMed ID: 25443997
[TBL] [Abstract][Full Text] [Related]
5. Failure of atovaquone-proguanil chemoprophylaxis and chloroquine treatment in Plasmodium malariae infection.
Visser R; de Mast Q; Munnix I; van der Ven A; Dofferhoff T
Travel Med Infect Dis; 2016; 14(6):644-645. PubMed ID: 27546283
[No Abstract] [Full Text] [Related]
6. Antimalarial pharmacology and therapeutics of atovaquone.
Nixon GL; Moss DM; Shone AE; Lalloo DG; Fisher N; O'Neill PM; Ward SA; Biagini GA
J Antimicrob Chemother; 2013 May; 68(5):977-85. PubMed ID: 23292347
[TBL] [Abstract][Full Text] [Related]
7. Atovaquone and proguanil hydrochloride for treatment of malaria.
Kremsner PG; Looareesuwan S; Chulay JD
J Travel Med; 1999 May; 6 Suppl 1():S18-20. PubMed ID: 23573548
[TBL] [Abstract][Full Text] [Related]
8. Atovaquone and proguanil hydrochloride for prophylaxis of malaria.
Shanks GD; Kremsner PG; Sukwa TY; van der Berg JD; Shapiro TA; Scott TR; Chulay JD;
J Travel Med; 1999 May; 6 Suppl 1():S21-7. PubMed ID: 23573549
[TBL] [Abstract][Full Text] [Related]
9. Drug-free Holidays: Compliance, Tolerability, and Acceptability of a 3-Day Atovaquone/Proguanil Schedule for Pretravel Malaria Chemoprophylaxis in Australian Travelers.
Lau CL; Ramsey L; Mills LC; Furuya-Kanamori L; Mills DJ
Clin Infect Dis; 2019 Jun; 69(1):137-143. PubMed ID: 30281083
[TBL] [Abstract][Full Text] [Related]
10. Questionnaire-based analysis of atovaquone-proguanil compared with mefloquine in the chemoprophylaxis of malaria in non-immune Japanese travelers.
Kato T; Okuda J; Ide D; Amano K; Takei Y; Yamaguchi Y
J Infect Chemother; 2013 Feb; 19(1):20-3. PubMed ID: 22740189
[TBL] [Abstract][Full Text] [Related]
11. A systematic review and meta-analysis of the effectiveness and safety of atovaquone proguanil (Malarone) for chemoprophylaxis against malaria.
Nakato H; Vivancos R; Hunter PR
J Antimicrob Chemother; 2007 Nov; 60(5):929-36. PubMed ID: 17848375
[TBL] [Abstract][Full Text] [Related]
12. Recognition and Management of Malaria.
Gerstenlauer C
Nurs Clin North Am; 2019 Jun; 54(2):245-260. PubMed ID: 31027664
[TBL] [Abstract][Full Text] [Related]
13. The safety of atovaquone-proguanil for the prevention and treatment of malaria in pregnancy: A systematic review.
Andrejko KL; Mayer RC; Kovacs S; Slutsker E; Bartlett E; Tan KR; Gutman JR
Travel Med Infect Dis; 2019; 27():20-26. PubMed ID: 30654041
[TBL] [Abstract][Full Text] [Related]
14. Malaria chemoprophylaxis regimens: a descriptive drug utilization study.
Bloechliger M; Schlagenhauf P; Toovey S; Schnetzler G; Tatt I; Tomianovic D; Jick SS; Meier CR
Travel Med Infect Dis; 2014; 12(6 Pt B):718-25. PubMed ID: 24934849
[TBL] [Abstract][Full Text] [Related]
15. Relapsing malaria: two cases of malaria presenting 8 months after return from Africa despite adherence to antimalarial chemoprophylaxis.
Morgan GS; Chiodini P; Evans M
Br J Gen Pract; 2012 Oct; 62(603):555-6. PubMed ID: 23265223
[No Abstract] [Full Text] [Related]
16. New options for the prevention and treatment of malaria: focus on the role of atovaquone and proguanil hydrochloride.
Shanks GD
J Travel Med; 1999 May; 6 Suppl 1():S1. PubMed ID: 23573544
[No Abstract] [Full Text] [Related]
17. Further observation of travellers taking twice-weekly atovaquone-proguanil prophylaxis in sub-Saharan Africa.
Biber A; Harel R; Schwartz E
J Travel Med; 2019 Jun; 26(4):. PubMed ID: 30690466
[No Abstract] [Full Text] [Related]
18. In Vitro Analysis of the Interaction between Atovaquone and Proguanil against Liver Stage Malaria Parasites.
Barata L; Houzé P; Boutbibe K; Zanghi G; Franetich JF; Mazier D; Clain J
Antimicrob Agents Chemother; 2016 Jul; 60(7):4333-5. PubMed ID: 26926628
[TBL] [Abstract][Full Text] [Related]
19. Antimalarial chemoprophylaxis and treatment in the USA: limited access and extreme price variability.
Frosch AE; Thielen BK; Alpern JD; Walz EJ; Volkman HR; Smith M; Wanduragala D; Holder W; Boumi AE; Stauffer WM
J Travel Med; 2022 Jul; 29(4):. PubMed ID: 34343310
[No Abstract] [Full Text] [Related]
20. On the potential for discontinuing atovaquone-proguanil (AP) ad-hoc post-exposure and other abbreviated AP-regimens: Pharmacology, pharmacokinetics and perspectives.
Schnyder JL; de Jong HK; Bache EB; van Hest RM; Schlagenhauf P; Borrmann S; Hanscheid T; Grobusch MP
Travel Med Infect Dis; 2023; 52():102520. PubMed ID: 36526126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
